Novartis Challenger To Alexion Advances In Rare Kidney Disease

Ultomiris Head-to-Head Planned

 
• By Andrew McConaghie

First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.

Novartis NIBR Cambridge, MA
Analysts at Jefferies think iptacopan could hit $3.6bn in peak annual sales. • Source: Alamy

More from Business

More from Scrip